Image: Kymab
Wellcome-backed Kymab snapped up by French biotech company
Biotech giant Sanofi is to buy Cambridge-based company Kymab in a deal potentially worth over £1 billion.
In 2010, Kymab became the first spin-out company to emerge from the UK’s lauded Wellcome Trust Sanger Institute, based on work by Sanger researcher Allan Bradley and funded initially by $30 million (£22m) from the Wellcome Trust Investment Division.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.